Newsroom Archives - Spectral Medical Inc

Spectral Medical Supports World Sepsis Day

World Sepsis Day is Today, September 13, 2023 TORONTO, Canada – September 13, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to support...

Spectral Medical Featured in New Episode of ‘The Balancing Act’ Airing on Lifetime TV Focused on Endotoxic Septic Shock

Episode to be Broadcast on Monday, September 11th and Tuesday, September 19th, 2023 at 7:30 a.m. (ET/PT) TORONTO, Canada – September 8, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing...

Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing

Tigris patient enrollment momentum continues reaching 72 The Company anticipates three additional trial sites to be activated in Q3 NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Canada – September 7, 2023...

Spectral Medical Inc. Announces Upsizing of Previously Announced Bought Deal Convertible Note Financing to C$5.5M

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA. TORONTO, Canada –...

Spectral Medical Highlights New Episode of ‘The Balancing Act’ Airing on Lifetime TV Focused on Endotoxic Shock

Episode to be Broadcast on September 11th, 2023, at 7:30 a.m. (ET/PT) preceding World Sepsis Day on September 13th TORONTO, Canada – August 16, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing...

Spectral Medical Inc. Announces C$5 Million Bought Deal Convertible Note Financing

« Older Entries

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.